Compare USPH & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | USPH | GPCR |
|---|---|---|
| Founded | 1990 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 1992 | 2023 |
| Metric | USPH | GPCR |
|---|---|---|
| Price | $79.02 | $60.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $108.20 | $94.90 |
| AVG Volume (30 Days) | 199.5K | ★ 2.6M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.22% | N/A |
| EPS Growth | ★ 153.49 | N/A |
| EPS | ★ 2.38 | N/A |
| Revenue | ★ $750,948,000.00 | N/A |
| Revenue This Year | $19.53 | N/A |
| Revenue Next Year | $6.33 | N/A |
| P/E Ratio | $33.03 | ★ N/A |
| Revenue Growth | ★ 17.51 | N/A |
| 52 Week Low | $62.77 | $13.22 |
| 52 Week High | $98.07 | $94.90 |
| Indicator | USPH | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 54.36 | 67.00 |
| Support Level | $74.08 | $58.84 |
| Resistance Level | $82.46 | $72.39 |
| Average True Range (ATR) | 2.71 | 6.91 |
| MACD | 0.96 | 1.70 |
| Stochastic Oscillator | 66.54 | 46.64 |
US Physical Therapy Inc through its subsidiaries operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal payment sources for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.